Ofelia Marin
Pediatric Gastroenterology · Naples, FLNPI 1740359900
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,837 of the $6,106 with a category attached, or 79.2%. 16 manufacturers reported payments, led by AbbVie at 36.5% of the total. Reporting peaked in 2019 at $1,992 and has fallen 86.7% since, to $265 in 2025.
Across 161 payments — averaging $37.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Sanofi$505
- Cumberland Pharmaceuticals, Inc.$363
- Johnson & Johnson$358
- Nestle Healthcare Nutrition Inc.$331
- plus $1K from 10 others
What the payments were for
- Speaking & faculty fees$1,22520%
- Food & beverage$4,83779%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 67 | $2,228 |
| AstraZeneca | 6 | $1,316 |
| Sanofi | 12 | $505 |
| Cumberland Pharmaceuticals, Inc. | 11 | $363 |
| Johnson & Johnson | 4 | $358 |
| Nestle Healthcare Nutrition Inc. | 12 | $331 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $237 |
| Regeneron Healthcare Solutions, Inc. | 10 | $232 |
| Ipsen Biopharmaceuticals, Inc | 5 | $193 |
| QOL Medical, LLC | 8 | $108 |
| Travere Therapeutics, Inc. | 12 | $87 |
| Mirum Pharmaceuticals, Inc. | 2 | $42 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Albireo Pharma, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,106 in reported general payments places this provider in the 80th percentile of 128 pediatric gastroenterology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 11 | $82,328 |
| RinvoqUpadacitinib | 11 | $80,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,228 | $80,57711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 128 pediatric gastroenterology providers in Florida.
Other pediatric gastroenterology in Naples
- Aymin DelgadoNaples$45K
- Yamen SmadiOrlando$593K
- Regino Gonzalez-PeraltaOrlando$285K
- Akash PandeyOrlando$99K
- Shaista SafderOrlando$80K
- Alisa Muniz CrimMiami$50K
- Sara KarjooSt Petersburg$43K
- Jeffrey BornsteinOrlando$35K
- Debora DuroFort Lauderdale$26K
- Stefany Hernandez BenabeOrlando$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.